Multicenter Italian Trials in Ovarian Cancer   Report issue

Academic/Hospital Phase 2 Phase 3
Founded: Italy (1998)

Organization Overview

First Clinical Trial
2014
NCT02009579
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Multicenter Italian Trials in Ovarian cancer and gynecologic malignancies (MITO) | Multicenter Italian Trials in Ovarian Cancer (MITO)

Active Ingredients

Drugs in Phase 3 Trials (1)

olaparib (lynparza) (1 trial)

Drugs in Phase 2 Trials (3)

letrozole (femara) (1 trial)

nintedanib (ofev) (1 trial)

palbociclib (ibrance) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Ovarian Epithelial (Phase 3)

Endometrial Neoplasms (Phase 2)

Ovarian Neoplasms (Phase 3)

Uterine Cervical Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 4